01 2Onglyza
02 2Onglyza/Kombiglyze XR/Komboglyze
03 1Seloken
04 1Seloken /Toprol-XL
05 7Seloken/Toprol-XL
06 1Seloken/Toprol-XL
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 821
2019 Revenue in Millions : 760
Growth (%) : 8
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 951
2020 Revenue in Millions : 821
Growth (%) : 16
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 360
2020 Revenue in Millions : 470
Growth (%) : -23
Main Therapeutic Indication : Diabetes
Currency : USD
2022 Revenue in Millions : 257
2021 Revenue in Millions : 360
Growth (%) : -29
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 862
2021 Revenue in Millions : 951
Growth (%) : -9
Main Therapeutic Indication : Diabetes
Currency : USD
2023 Revenue in Millions : 227
2022 Revenue in Millions : 257
Growth (%) : -12
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 640
2022 Revenue in Millions : 862
Growth (%) : -26
Main Therapeutic Indication : Antihypertensives
Currency : USD
2015 Revenue in Millions : 758
2014 Revenue in Millions : 710
Growth (%) : -6%
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2017 Revenue in Millions : 695
2016 Revenue in Millions : 737
Growth (%) : -6
Main Therapeutic Indication : Antihypertensives
Currency : USD
2014 Revenue in Millions : 1.10%
2013 Revenue in Millions :
Growth (%) :
LOOKING FOR A SUPPLIER?